Syndax Pharmaceuticals, Inc. (SNDX) — Financial statements
Income statement, balance sheet, and cash flow for Syndax Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 172↑627.8% | 24 | 0.00 | 0.00↓100.0% | 140 | |
| Cost of Revenue | 7↑743.8% | 0.83 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 165↑623.6% | 23 | 0.00 | 0.00↓100.0% | 140 | |
| Operating Expenses | ||||||
| R&D Expenses | 259↑7.1% | 242↑48.2% | 163↑37.6% | 118↑34.3% | 88 | |
| General & Administrative Expenses | 180↑48.6% | 121↑80.6% | 67↑101.2% | 33↑31.8% | 25 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 180↑48.6% | 121↑80.6% | 67↑101.2% | 33↑31.8% | 25 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 438↑20.9% | 363↑57.7% | 230↑51.5% | 152↑33.7% | 113 | |
| Total Costs & Expenses | 445↑22.6% | 363↑58.0% | 230↑51.5% | 152↑33.7% | 113 | |
| Operating Results | ||||||
| Operating Income | -273↑19.6% | -340↓47.7% | -230↓51.5% | -152↓678.8% | 26 | |
| Depreciation & Amortization | 0.01↓25.0% | 0.01↓33.3% | 0.01↓63.6% | 0.03↓23.3% | 0.04 | |
| EBITDA | -252↑19.8% | -314↓50.1% | -209↓43.1% | -146↓644.0% | 27 | |
| EBIT | -252↑19.8% | -314↓50.0% | -209↓43.1% | -146↓645.0% | 27 | |
| Interest & Other Income | ||||||
| Net Interest Income | -11↓152.2% | 21↑1.0% | 21↑666.2% | 3↑282.8% | -1 | |
| Interest Income | 23↓12.9% | 26↑23.3% | 21↑260.4% | 6↑1357.1% | 0.40 | |
| Interest Expense | 34↑585.4% | 5↑2269.7% | 0.21↓93.4% | 3↑65.2% | 2 | |
| Non-Operating Income | -21↑17.0% | -26↓24.2% | -21↓274.4% | -6↓818.3% | -0.61 | |
| Other Income / Expenses | -12↓159.0% | 21↑1.6% | 21↑751.3% | 2↑286.9% | -1 | |
| Income Before Tax | -285↑10.5% | -319↓52.3% | -209↓40.2% | -149↓699.1% | 25 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -285↑10.5% | -319↓52.3% | -209↓40.2% | -149↓699.1% | 25 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -285↑10.5% | -319↓52.3% | -209↓40.2% | -149↓699.1% | 25 | |
| Bottom-Line Net Income | -285↑10.5% | -319↓52.3% | -209↓40.2% | -149↓699.1% | 25 | |
| EPS (Basic) | -3.29↑11.8% | -3.73↓25.2% | -2.98↓21.1% | -2.46↓612.5% | 0.48 | |
| EPS (Diluted) | -3.29↑11.8% | -3.73↓25.2% | -2.98↓21.1% | -2.46↓612.5% | 0.48 | |
| Weighted Average Shares | 87↑1.2% | 86↑21.7% | 70↑15.8% | 61↑16.7% | 52 | |
| Weighted Average Diluted Shares | 87↑1.2% | 86↑21.7% | 70↑15.8% | 61↑16.7% | 52 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.